Why implementing machine learning algorithms in the clinic is not a plug-and-play solution: a simulation study of a machine learning algorithm for acute leukaemia subtype diagnosis.

EBioMedicine

Department of Haematology & Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, Essen, Germany; Laboratory for Clinical Research and Real-World Evidence, Institute for Artificial Intelligence in Medicine, University Hospital Essen, Essen, Germany. Electronic address:

Published: December 2024

AI Article Synopsis

  • The study evaluated the performance of the AI-PAL machine learning algorithm for diagnosing acute leukaemia when implemented in a real-world clinical setting at the University Hospital Essen.
  • Results showed that the AI-PAL algorithm performed significantly worse in the clinical simulation compared to previous results, with key performance metrics falling below the expected levels.
  • The findings highlight the necessity for local validation and potential recalibration of machine learning models before their use in clinical settings to ensure they are reliable and safe for patient care.

Article Abstract

Background: Artificial intelligence (AI) and machine learning (ML) algorithms have shown great promise in clinical medicine. Despite the increasing number of published algorithms, most remain unvalidated in real-world clinical settings. This study aims to simulate the practical implementation challenges of a recently developed ML algorithm, AI-PAL, designed for the diagnosis of acute leukaemia and report on its performance.

Methods: We conducted a detailed simulation of the AI-PAL algorithm's implementation at the University Hospital Essen. Cohort building was performed using our Fast Healthcare Interoperability Resources (FHIR) database, identifying all initially diagnosed patients with acute leukaemia and selected differential diagnoses. The algorithm's performance was assessed by reproducing the original study's results.

Findings: The AI-PAL algorithm demonstrated significantly lower performance in our simulated clinical implementation compared to prior published results. The area under the receiver operating characteristic curve for acute lymphoblastic leukaemia dropped to 0.67 (95% CI: 0.61-0.73) and for acute myeloid leukaemia to 0.71 (95% CI: 0.65-0.76). The recalibration of probability cutoffs determining confident diagnoses increased the number of confident positive diagnosis for acute leukaemia from 98 to 160, highlighting the necessity of local validation and adjustments.

Interpretation: The findings underscore the challenges of implementing ML algorithms in clinical practice. Despite robust development and validation in research settings, ML models like AI-PAL may require significant adjustments and recalibration to maintain performance in different clinical settings. Our results suggest that clinical decision support algorithms should undergo local performance validation before integration into routine care to ensure reliability and safety.

Funding: This study was supported by the DFG-cofounded UMEA Clinician Scientist Program and the Ministry of Culture and Science of the State of North Rhine-Westphalia.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2024.105526DOI Listing

Publication Analysis

Top Keywords

acute leukaemia
16
machine learning
12
learning algorithms
8
clinical settings
8
diagnosis acute
8
acute
6
leukaemia
6
clinical
6
algorithms
5
implementing machine
4

Similar Publications

Hepatitis B virus (HBV) reactivation is a recognized complication of long-term immunosuppressive or cytotoxic therapy, typically occurring during immunosuppression or within a few months after treatment. To mitigate this risk, hepatological societies recommend the use of nucleos(t)ide analogues (NA) for HBV reactivation prophylaxis, along with post-treatment monitoring; though, these recommendations are not universally consistent across different guidelines. We present a case of late HBV reactivation in a 76-year-old male with occult HBV infection who received rituximab-based therapy for chronic lymphocytic leukemia.

View Article and Find Full Text PDF

Acute myeloid leukemia (AML), which is most common in adults, is a challenging hematological malignancy. The occurrence and the progression of AML are often accompanied by various gene fusions and/or mutations. Herein, we report the first case of a fusion transcript with a translocation of (1;12)(q25;p13) in AML progressed from myelodysplastic syndrome (MDS) combined with an -ITD (internal tandem duplication) mutation.

View Article and Find Full Text PDF

Invasive mucormycosis is an aggressive fungal infection characterized by rapid progression, primarily impacting immunocompromised individuals. Herein, we report a case of splenic infarction in association with gastrointestinal fistula and brain abscess as a rare presentation of mucormycosis biopsy, proven in a 56-year-old patient diagnosed with acute myeloid leukemia. The patient initially sought medical attention with a 3-week history of fever, night sweats, and malaise.

View Article and Find Full Text PDF

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by damage to organs and cells, initially mediated by tissue-binding autoantibodies and immune complexes. Lymphomas have been frequently reported, but the association of SLE with acute leukemia is rare and likely coincidental. We report a case of a 40-year-old female admitted for an etiological diagnosis of fever and dyspnea with peripheral edema.

View Article and Find Full Text PDF

Renal cell carcinoma (RCC) is the most common malignancy that metastasizes to the thyroid; however, metastasis of RCC to a primary tumor of the thyroid is rare. The present study reports the case of RCC that had metastasized to the primary thyroid tumor; namely, a hyalinizing trabecular tumor (HTT). Notably, the RCC was resected 2 years prior.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!